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Abstract: Infection and inflammation remain a major cause of mortality and morbidity globally. This promotes research 
into better and more accurate diagnostic and therapeutic methods. This investigation focused on the labeling of 
sarafloxacin and danofloxacin for infection imaging. The radiolabeled antibiotic 
99m
Tc-sarafloxacin and 
99m
Tc-danofloxacin 
were assessed as an infection imaging agent in a mouse model. 
99m
Tc-sarafloxacin and 
99m
Tc-danofloxacin were obtained at 
pH 11 with a radiochemical yield of 96, 90%, respectively by adding 
99m
Tc to 1 mg sarafloxacin or danofloxacin in the 
presence of 50 μg SnCl2.2H2O. Biodistribution studies in mice were carried out in experimentally induced infection in the 
left thigh using Staphylococcus aureus. Both thighs of the mice were dissected and counted and the ratio of bacterial 
infected thigh/contralateral thigh was then evaluated. 
99m
Tc-sarafloxacin and 
99m
Tc-danofloxacin showed high uptake (T/NT 
=3.8±0.1 and 4.9±0.1, respectively) in the infectious lesion and abscess to normal muscle ratio indicating that 
99m
Tc-
sarafloxacin and 
99m
Tc-danofloxacin could be used for infection imaging. 
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Introduction 
 
Even in most recent decades, infection and inflammation remain a major cause of mortality and 
morbidity globally. Infections, especially internal Infections, resulting in delayed diagnosis, treatment, 
and sometimes death, were difficult to detect in the early stages. Clinicians use a variety of clues, e.g., 
clinical, laboratory, and radiological tests, to give a good diagnosis of infection as early as possible. 
Several imaging methods like ultrasonography (US), computer tomography (CT) and magnetic 
resonance imaging (MRI) are available and have been used for the past several decades for the 
localization of infection. It is well known that these are not the best of methods for the localization of 
infection at early stages. These procedures detect the morphologic alterations of the tissues after 
abscess formation. 
(1)
 These may take some time to become visible, may not always be present, and 
their resolution lags behind the cure of the infection. In addition, they are neither infection nor 
inflammation specific. The introduction of radiopharmaceuticals in nuclear medicine has enhanced 
infection imaging, because it depends on the demonstration of pathophysiological and pathobiological 
changes, which occur earlier in the infection process and also resolve quicker after cure of the infection 
compared with gross changes in structure. Clearly, radiopharmaceuticals that bind to a variety of 
bacteria would be better candidates for specific infection imaging 
(2)
.  
 
Quinolone drugs are large and widely used class of synthetic antibacterial compounds. 
(3–5)
 First 
generation quinolones include naldexic acid and oxolinic acid. Subsequent generations have been 
modified to increase spectrum and potency. The most significant modification has been the addition of 
a fluorine atom in drugs such as sarafloxacin and danofloxacine (Figure 1) is the 
4
th generation of 
quinolone antibiotics that has activity against a wide range of Gram-negative and Gram-positive 
microorganisms. Sarafloxacin and danofloxacin showed widespread distribution into body tissues and it 
was stereochemically stable in plasma and urine.  
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Sarafloxacin and danofloxacin undergoe limited metabolism in humans and excreted as unchanged 
drug in the urine that used safely in patients with impaired renal functions and hepatic insufficiency. 
Quinolones target bacterial type topoisomerase II ‗DNA gyrase‘ in Gram-negative bacteria and DNA 
topoisomerase IV in Gram-positive bacteria.2 Nuclear medicine techniques are used in the context of 
infection localization. Inflammation imaging agents such as polyclonal and monoclonal antibodies, 
peptides, 
(6–8)
 cytokines, 
(9)
 and HMPAO-leukocytes 
(10, 11)
 cannot discriminate between septic and 
sterile inflammatory sites. A novel approach using a bacterially binding radiolabeled antimicrobial 
agent to detect infections was introduced since 1996 by Vinjamuri and Co-workers 
(12) 
when they 
labeled ciprofloxacin with technetium-99m, and clinically used under the trade name ‗Infecton‘. 99mTc-
ciprofloxacin preparation has some disadvantages related to radiochemical purity (81%±4)
(14)
 and 
stability which are discussed in details in the literature.
(1,13,14–18)  
Later, many fluoroquinolones 
antimicrobial agents which not have the drawbacks of ciprofloxacin on patients suffering from kidney 
failure, congenital abnormalities of the urinary tract, urinary tract obstruction, pyelonephritis were 
labeled with technetium-99m and evaluated as infection imaging agents.
(19)
 During this study, 
sarafloxacin and danofloxacin were labeled with technetium-99m and the parameters affecting this 
labeling reaction were studied. The labeled sarafloxacin and danofloxacin were evaluated biologically 
in normal and in inflamed mice. 
       
         Ciprofloxacin                           Sarafloxacin               Danofloxacin 
 
Figure (1): Chemical structure of ciprofloxacin, sarafloxacin and danofloxacin 
 
Experimental 
Sarafloxacin and danofloxacin were purchased from Sigma-Aldrich Chemical Company, USA, and all 
other chemicals were purchased from Merck and they were reactive grade. 
 
Method 
 
Labeling procedure: Accurately weighed 1 mg sarafloxacin or danofloxacin was transferred to an 
evacuated penicillin vial. Exactly 50 μg SnCl2 solution was added and the pH of the mixture was 
adjusted to 11 using 0.1N NaOH, then the volume of the mixture was adjusted to one ml by N2-purged 
distilled water. One ml of freshly eluted 
99m
TcO4
– 
(400 MBq) was added to the above mixture. The 
reaction mixture was vigorously shaken and allowed to react at room temperature for sufficient time to 
complete the reaction. 
 
Analysis: The percent labeling yield was determined by using ascending paper chromatography. Paper 
strips of silica gel impregnated glass fiber sheets (ITLC-SG), 10×1.5 cm2, were marked gently with a 
pencil at a distance of 2 cm from the lower end.  
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A spot of the reaction mixture was applied at this line, and then the strip was developed in an 
ascending manner in a closed jar filled with N2 gas to prevent oxidation of the labeled complex. The 
developing solvents were acetone and ethanol :water :ammonium hydroxide mixture (2:5:1) purged 
with N2 gas. After complete development, the strip was dried and counted in a well-type γ-scintillation 
counter. The organic solvent acetone was used to calculate the percentage of free 
99m
TcO4
–
 which 
moved with the solvent front (Rf = 1) leaving the labeled complex and colloid at the origin. Ethanol: 
water: ammonium hydroxide mixture (2:5:1) was used to check the amount of reduced hydrolyzed 
technetium which remains at the origin (Rf = 0) while other species migrate with the solvent front (Rf 
= 1). The radiochemical purity was determined by subtracting the sum of the % of colloid and free 
pertechnetate from 100%. The radiochemical yield is the mean value of three experiments. 
 
Bio-distribution studies 
 
Induction of infectious foci 
The inflammations were induced via intramuscular injection of the approximately 10
5–106 colony 
forming units of Staphylococcus aureus suspended in 0.2 ml of saline (model for septic inflammation). 
Groups of 3 mice, weighing approximately 25 g each, were injected with 200 µl of the above 
suspension in the right thigh muscle.
(20) 
Twenty-four hours required to get gross swelling in 
theinfected thighs. 
 
Induction of non-infected inflammation 
Sterile inflammation was induced by injecting 200 µl of turpentine oil (21) which was sterilized by 
autoclaving at 121 °C for 20 minutes and heat killed Staphylococcus aureus (model for pyrogen 
induced inflammation), intramuscularly (i.m.) in the right lateral thigh muscle of the albino mice. Two 
days later, swelling appeared. 
The animals were intravenously injected with 100 µl (100-150 MBq) 
99m
Tc-sarafloxacin and 
99m
Tc-
danofloxacin via the tail vein and kept alive in metabolic cage for different intervals of time under 
normal conditions. 
The mice were sacrificed at 2, 4 and 24-hour post-injection. Samples of fresh blood, bone and muscle 
were collected in pre-weighed vials and counted. The different organs were removed, counted and 
compared to a standard solution of the labeled sarafloxacin and danofloxacin. The average percent 
values of the administrated dose/organ were calculated. Blood, bone and muscles were assumed to be 
7, 10 and 40%, respectively, of the total body weight. 
(22)
 Corrections were made for background 
radiation and physical decay during experiment. Both target and non-target thighs were dissected and 
counted. 
 
Results and discussion 
Effect of substrate concentration 
As shown in Fig. 2, at low substrate concentration (0.5 mg) the yield was small and equal to 35 and 
36.4% for 
99m
Tc-sarafloxacin and 
99m
Tc-danofloxacin, respectively. These low labeling yields were 
due to the substrate concentrations being insufficient to form the complex with all of the reduced 
technetium while the percentage of colloid was high (62 and 53%, respectively). Increasing the 
substrate concentration lead to higher labeling yield and the maximum yield was achieved at 1 mg for 
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sarafloxacin and danofloxacin. By increasing the substrate concentration over the optimum values, the 
labeling yield was slightly decreased. 
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Figure 2: Effect of substrate content on the percent labeling yield of 
99m
Tc-sarafloxacin and 
99m
Tc-danofloxacin complex 
 
Effect of SnCl2 concentration 
 
The results obtained in the figure 3 showed that, at pH 11 efficient labeling yield was achieved by using 
the optimum amount of Sn (II) µg at which a maximum labeling of 96 andwhich was equal to 50 90%
 
for
 99m
Tc-sarafloxacin and 
99m
Tc-danofloxacin, respectively was obtained. Below this value, stannous 
chloride is not sufficient for complete reduction of pertechnetate to form 
99m
Tc-complex, this is an 
explanation of the presence of high percentage of free pertechnetate  (18 µg tin (II)) and 24% at 25. By 
increasing the amount of SnCl2.2H2O above 50µg, the yield drastically decreased while the amount of 
colloid increase and reach to 71 and 47.7% for sarafloxacin and danofloxacin at 200 µg SnCl2.2H2O, 
respectively. This may be due to excess SnCl2.2H2O was converted to tin colloid which competes with 
saraflxacin and danofloxacin for reduced 
99m
TcO4
-
. 
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Figure 3: Effect of Tin (II) content on the percent labeling yield of 99mTc-sarafloxacin and 99mTc-
danofloxacin complex 
Proceedings of Basic and Applied Sciences  
 ISSN 1857-8179 (paper). ISSN 1857-8187 (online). http://www.anglisticum.mk   
 Proceedings of the 1st International Conference on New Horizons in Basic and Applied Science, Hurghada – Egypt, Vol 1(1), 2013.  
397 
© The authors. Published by Info Media Group & Anglisticum Journal, Tetovo, Macedonia. 
Selection and peer-review under responsibility of ICNHBAS, 2013 http://www.nhbas2013.com 
 
 
Effect of pH of the reaction mixture 
 
Figure 4 clearly shows that the maximum radiochemical purity of the preparation was obtained at a pH 
11 and was equal to 96 and 90% for sarafloxacin and danofloxacin, respectively. At pH below or above 
the optimum pH, the radiochemical purity is significantly decreased by forming RH-
99m
Tc which is the 
main radiochemical impurities which was equal to 62 and 45.5%, respectively at pH 12.  
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Figure 4: Effect of pH value of the reaction mixture on the percent labeling yield of 
99m
Tc-sarafloxacin and 
99m
Tc-danofloxacin complex 
 
Effect of reaction time and stability test:   
 
Figure 5 show the rate of formation of 
99m
Tc-sarafloxacin and 
99m
Tc-danofloxacin started relatively 
slowly with a yield of ~ 89 and 85%, respectively at 1 minute. The highest yield of 96 and 90%%, 
respectively were achieved at 30 minutes reaction time. Figure 6 show stability test where the two 
99m
Tc-complex were stable up to 4 hr, after that the yield decreased again. The colloid was the main 
impurity which was easily eliminated using a millipore filter (0.22 µm). 
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Figure 5: Effect of reaction time on
99m
Tc-sarafloxacin and
 99m
Tc-danofloxacin 
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Figure 6: Stability test for 
99m
Tc-sarafloxacin and 
99m
Tc-danofloxacin 
 
 
Biodistribution 
 
Based on the data presented in Tables (1-3), which clearly show the  biodistribution analysis of 
99m
Tc-
sarafloxacin, 
99m
Tc-danofloxacin and  
99m
Tc-ciprofloxacin complex in abscess and aseptic 
inflammation-bearing mice (heat killed bacteria and turpentine oil) at different time intervals post 
injection. These data depicted rapid distribution throughout the body and uptake in the inflamed areas 
was observed within 2 hours after intravenous injection of the tracer. As shown in figure (7, 8), mice 
with infectious lesions injected with 
99m
Tc-sarafloxacin and 
99m
Tc-danofloxacin showed a mean 
abscess-to-muscle (target-to-non target, T/NT) ratio equal to 3.8±0.1 and 4.9±0.1, after 2 h post 
injection. These 
99m
Tc-fluoroquinolones showed similar uptake in infected tissue to 
99m
Tc-ciprofloxacin 
(T/NT = 3.6±0.4). 
(23)
  The above results showed that no significant difference in T/NT of 
99m
Tc-
sarafloxacin and 
99m
Tc danofloxacin in septic and aseptic inflammation indicated that these 
99m
Tc-
fluoroquinolones can not differentiate between infection and sterile inflammation. 
 
Table 1: Biodistribution of 
99m
Tc-sarafloxacin in Staphylococcus aureus, heat killed Staphylococcus aureus 
and turpentine oil inflamed rats at different time intervals 
 
Organs and body fluids             % injected dose/organs at different time intervals (h) 
 
                              s. aureus                   heat killed s. aureus                  turpentine oil 
 
                  2             4             24                2                4                     24      2       4       24  
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Inflamed      1.09±0.2   0.84±0.11    0.58±0.06          1.11±0.1     0.85±0.2    0.54±0.1      0.58±0.0     
0.38±0.2     0.23±0.1 muscle 
Control       0.28±0.1    0.22±0.2     0.16±0.0          0.3±0.0       0.25±0.1   0.17±0.0         0.29±0.0    
0.23±0.0   0.14±0.0 
muscle 
Liver          19.1±3.2     14.9±2.0     7.4±0.3          20.6±2.4       15.2±2.2     7.9±0.5        19.5±3.0    
15.2±2.2      8.1±0.6 
Urine         20.5±3.5     26.8±4.2    31.9±3.1         19.1±1.3       27.3±1.1    33.4±2.7       19.0±0.9    
27.4±1.8     31.8±2.4 
Kidneys    12.5±1.2   11.9±1.3        8.6±0.4           13.9±1.3      13.2±2.3     8.5±0.7        13.3±2.5    
13.2±1.2      7.9±0.3 
Blood        6.9±0.4      4.5±0.2         1.00±0.0         7810±0.2       6.0±0.2       1.3±0.1       6.0±0.2      
4.5±0.2       1.0±0.0 
Heart         0.8±0.1    0.2±0.0          0.1±0.0         0.3±0.09       0.2±0.0       0.1±0.0         0.4±0.08    
0.2±0.0       0.1±0.0 
Lung         1.4±0.2     0.4±0.0          0.1±0.0           1.2±0.09       0.3±0.0       0.1±0.0      1.4±0.09     
0.4±0.1      0.2±0.0 
Intestine    21.9±2.5   5.90±0.5       4.10±0.3          22.1±3.4        6.7±0.4       4.6±0.7      19.9±1.9    
6.7±0.8      4.4±0.4 
and stomach 
Spleen       2.10±0.1   1.10±0.2       0.3±0.1            2.5±0.3         1.6±0.0        0.5±0.1       2.3±0.1     
1.4±0.0       0.4±0.0 
Bone          1±0.1          0.60±0.1       0.30±0.0          1.2±0.0          0.5±0.1        0.3±0.0       1.1±0.2     
0.5±0.1       0.1±0.0 
 
 
Table 2: Biodistribution of 
99m
Tc-danofloxacin in Staphylococcus aureus, heat killed 
Staphylococcus aureus and turpentine oil inflamed rats at different time intervals 
 
Organs and body fluids             % injected dose/organs at different time intervals (h) 
 
                     s. aureus                           heat killed s. aureus                    turpentine oil 
 
                   2            4             24                 2                4                   24       2       4       24  
 
Inflamed      1.37±0.2   0.95±0.11    0.76±0.06          1.15±0.1     0.96±0.2    0.48±0.1        0.78±0.0      
0.50±0.2     0.22±0.1  
muscle                                                                                                                  
Control       0.28±0.1    0.21±0.2     0.19±0.0          0.29±0.0       0.26±0.1   0.15±0.0         0.31±0.0    
0.25±0.0   0.13±0.0 
muscle                                                                                                             
Liver         17.1±3.2     12.9±2.0     5.4±0.3          17.6±2.4       12.2±2.2     4.9±0.5        17.5±3.0    
13.2±2.2      6.1±0.6  
Urine        18.5±3.5     24.9±4.2    29.9±3.1         17.1±1.3       24.3±1.1    29.4±2.7       18.0±0.9    
25.4±1.8     28.8±2.4  
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Kidneys    11.2±1.2   10.7±1.3        6.6±0.4           10.9±1.3      10.2±2.3     5.5±0.7        11.3±2.5    
10.2±1.2      6.9±0.3 
Blood        5.3±0.4      3.1±0.2         1.00±0.0         6.10±0.2       4.0±0.2       1.0±0.1       5.5±0.2      
4.3±0.2       1.0±0.0 
Heart         0.3±0.1    0.1±0.0          0.09±0.0         0.3±0.09       0.1±0.0       0.1±0.0         0.4±0.08    
0.2±0.0       0.1±0.0 
Lung         1.2±0.2     0.2±0.0          0.1±0.0           1.1±0.09       0.2±0.0       0.1±0.0        1.3±0.09     
0.4±0.1      0.2±0.0 
Intestine    19.9±2.5   3.90±0.5       2.10±0.3          19.1±3.4        4.7±0.4       2.2±0.7        18.9±1.9    
4.7±0.8      2.4±0.4 
and stomach                                                           
Spleen       2.10±0.1   1.00±0.2       0.3±0.1            2.1±0.3         1.1±0.0        0.5±0.1       2.0±0.1     
1.3±0.0       0.3±0.0  
Bone         0.90±0.1   0.40±0.1       0.10±0.0         1.0±0.0          0.49±0.1      0.1±0.0       1.1±0.2     
0.5±0.1       0.1±0.0 
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Figure (7) target (T) to non-target (NT) ratio of 
99m
Tc-sarafloxacin when injected intravenous in mice at 
different post injection time 
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Figure (8) target (T) to non-target (NT) ratio of 
99m
Tc-danofloxacin when injected intravenous in mice at 
different post injection time 
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Conclusions 
 
99m
Tc-sarafloxacin and
 99m
Tc-danofloxacin were labeled easily at pH 11 using 50 μg SnCl2.2H2O as a 
reducing agent with a high labeling yield of 96 and 90%, respectively which higher than that of the 
commercially available 
99m
Tc-ciprofloxacin. The formation of 
99m
Tc-sarafloxacin and 
99m
Tc-
danofloxacin start slowly and reaches its maximum at 30 minutes. The 
99m
Tc-sarafloxacin and 
99m
Tc-
danofloxacin complexes were stable up to 4 hours, then the yield decreased (>80%). Biodistribution 
studies showed that, 
99m
Tc-sarafloxacin and
 99m
Tc-danofloxacin can not distinguish infection from 
sterile inflammation.  
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